Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chemotherapy Near the End of Life

Chemotherapy Near the End of Life Chemotherapy Use, Performance Status, and Quality of Life Near Death Original Investigation Research Invited Commentary First—and Third and Fourth (Line)—Do No Harm Charles D. Blanke, MD; Erik K. Fromme, MD In reality, only 2 major reasons exist for administering che- current practice, and stand as a relative indictment of motherapy to most patients with metastatic cancer: to help routinely offering chemotherapy to patients with terminal them live longer and/or to help them live better. In exchange cancers. for treatment-related toxic effects (as well as substantial time, It is not surprising that chemotherapy did not improve expense, and inconvenience), QOL for most patients. The measurement focused on the last chemotherapy can prolong week of life, when one would presume that other biomedical, Related article page 778 survival for patients with a psychosocial, or spiritual issues were weighing heavily upon variety of—though not all— the patients. But why should patients with the best (ECOG solid tumors. Chemotherapy may also improve quality of score = 1) performance status have poorer QOL at the end of life (QOL) for patients by reducing symptoms caused by a their lives when they received chemotherapy? One obvious malignancy. In this issue of JAMA Oncology, Prigerson and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Chemotherapy Near the End of Life

JAMA Oncology , Volume 1 (6) – Sep 1, 2015

Loading next page...
 
/lp/american-medical-association/chemotherapy-near-the-end-of-life-bFmqwPy8DA
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2015.2379
pmid
26203585
Publisher site
See Article on Publisher Site

Abstract

Chemotherapy Use, Performance Status, and Quality of Life Near Death Original Investigation Research Invited Commentary First—and Third and Fourth (Line)—Do No Harm Charles D. Blanke, MD; Erik K. Fromme, MD In reality, only 2 major reasons exist for administering che- current practice, and stand as a relative indictment of motherapy to most patients with metastatic cancer: to help routinely offering chemotherapy to patients with terminal them live longer and/or to help them live better. In exchange cancers. for treatment-related toxic effects (as well as substantial time, It is not surprising that chemotherapy did not improve expense, and inconvenience), QOL for most patients. The measurement focused on the last chemotherapy can prolong week of life, when one would presume that other biomedical, Related article page 778 survival for patients with a psychosocial, or spiritual issues were weighing heavily upon variety of—though not all— the patients. But why should patients with the best (ECOG solid tumors. Chemotherapy may also improve quality of score = 1) performance status have poorer QOL at the end of life (QOL) for patients by reducing symptoms caused by a their lives when they received chemotherapy? One obvious malignancy. In this issue of JAMA Oncology, Prigerson and

Journal

JAMA OncologyAmerican Medical Association

Published: Sep 1, 2015

References